• 146 Citations
20022018
If you made any changes in Pure these will be visible here soon.

Fingerprint Fingerprint is based on mining the text of the person's scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

  • 16 Similar Profiles
Tauopathies Medicine & Life Sciences
Alzheimer Disease Medicine & Life Sciences
Transgenic Mice Medicine & Life Sciences
Synucleins Medicine & Life Sciences
tau Proteins Chemical Compounds
Salts Chemical Compounds
Parkinson Disease Medicine & Life Sciences
Methylene Blue Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 2002 2018

4 Citations (Scopus)
14 Downloads (Pure)

Alpha-Synuclein transgenic mice, h-α-SynL62, display α-Syn aggregation and a dopaminergic phenotype reminiscent of Parkinson's disease

Frahm, S., Melis, V., Horsley, D., Rickard, J. E., Riedel, G., Fadda, P., Scherma, M., Harrington, C. R., Wischik, C. M., Theuring, F. & Schwab, K., 26 Feb 2018, In : Behavioural Brain Research. 339, p. 153-168 16 p.

Research output: Contribution to journalArticle

Open Access
File
alpha-Synuclein
Transgenic Mice
Parkinson Disease
Lewy Body Disease
Amphetamine
1 Citation (Scopus)
11 Downloads (Pure)
Open Access
File
Synucleins
Transgenic Mice
Proteins
Parkinson Disease
Endopeptidase K
2 Citations (Scopus)

Assays for the Screening and Characterization of Tau Aggregation Inhibitors

Rickard, J. E., Horsley, D., Wischik, C. M. & Harrington, C. R., 15 Dec 2016, Tau Protein: Methods and Protocols. Smet-Nocca, C. (ed.). Springer , Vol. 1523. p. 129-140 12 p. (Methods in Molecular Biology; vol. 1523).

Research output: Chapter in Book/Report/Conference proceedingChapter

tau Proteins
Tauopathies
Immunoassay
Recombinant Proteins
Alzheimer Disease
37 Citations (Scopus)
5 Downloads (Pure)
Open Access
File
Proteolysis
Alzheimer Disease
Agglomeration
Brain
Salts
52 Citations (Scopus)
Oxidation-Reduction
Stomach
Alzheimer Disease
Aptitude
Methylene Blue

Impacts

Discovery and commercialisation of an entirely new drug for the treatment of Alzheimer's disease

Claude Michel Wischik (Participant), Charles Robert Harrington (Participant), John Mervyn David Storey (Participant), Janet Elizabeth Rickard (Participant), David Horsley (Participant), Thomas Baddeley (Participant), Steven John Kemp (Participant), James Peter Sinclair (Participant), Claudia Zabke (Participant), F. Theuring (Participant), F Stamer (Participant), C Marshall (Participant)

Impact: Quality of life Impacts, Economic Impacts